This content is machine translated CKD in People with Type 2 Diabetes: Evidence-Based, Optimized Treatment SGLT-2 inhibitors and GLP-1 receptor agonists: significant improvement in renal outcomes Approximately 30–40% of patients with type 2 diabetes develop chronic kidney disease (CKD) over time. In “landmark” studies such as CREDENCE, DAPA-CKD, EMPA-KIDNEY, and several others, SGLT-2 (sodium-glucose-linked transporter 2)...…
View Post 11 min This content is machine translated Type 2 diabetes: cardiovascular risk reduction is realistic Modern active ingredients and lifestyle – every step counts Although diabetics have an increased risk of developing cardiovascular diseases such as myocardial infarction, heart failure or stroke, scientific data suggests that protective effects can be achieved through the best...…
View Post 6 min This content is machine translated Recognize CKD early and avoid dialysis Screen diabetics and hypertensive patients regularly and use modern therapies High blood pressure and diabetes are the main causes of CKD – early diagnosis and treatment can reduce the risk of kidney failure and cardiorenal complications. Regular screening of these...…
View Post 6 min This content is machine translated Type 2 diabetes - glycemic control and prevention of secondary diseases Utilizing pleiotropic cardio- and nephroprotective effects of SGLT-2-i and GLP-1-RA Type 2 diabetes is currently understood to be a multisystemic disease, with the prognosis being significantly influenced by cardiac and renal pathology. An early, multimodal therapeutic approach that goes beyond...…
View Post 9 min This content is machine translated Chronic kidney disease (CKD) Triage of high-risk patients – Update 2025 In the recent past, the nephroprotective treatment armamentarium has been significantly expanded. It is essential that impaired renal function is detected in good time in order for patients to receive...…
View Post 5 min This content is machine translated Glomerulonephritis: IgA nephropathy Pathogenesis-based and nephroprotective therapeutic approaches Immunoglobulin (Ig) A nephropathy is considered an important cause of end-stage renal failure. Therefore, from today’s perspective, IgA nephropathy should not be classified as a benign disease. Fortunately, the treatment...…
View Post 5 min This content is machine translated Type 2 diabetes and cardiovascular disease How to reduce the burden of disease and improve prognosis Type 2 diabetes is known to increase the risk of cardiovascular disease. The ADA guidelines updated in 2025 propose specific screening measures for heart failure, coronary heart disease and PAD....…
View Post 5 min This content is machine translated Type 2 diabetes and CKD: primary and secondary prevention Screening paves the way for the best possible cardiorenal protection The presence of type 2 diabetes is considered a risk factor for the development of chronic kidney disease (CKD). Simple screening measures based on blood and urine samples can detect...…
View Post 4 min This content is machine translated Study report: Obesity New findings on the effects of incretin analogs A study by Aronne et al. investigated the effects of the dual GLP1/GIP receptor agonist (RA) tirzepatide in obese patients when it is administered over a longer period of therapy...…
View Post 5 min This content is machine translated Type 2 diabetes: reduction of microvascular and macrovascular risks The extensive toolbox has a lot to offer The fact that most type 2 diabetics today aim for an HbA1c value of <7% is partly due to the results of the UKPDS. This landmark study showed that the…
View Post 4 min This content is machine translated Type 2 diabetes Patient-oriented and far-sighted treatment A personalized treatment strategy has become an important basic principle in diabetes therapy. In addition to taking into account inter-individual differences in patient characteristics, certain clusters in relation to the…
